{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T07:16:15Z","timestamp":1763968575417,"version":"3.38.0"},"reference-count":8,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Eli Lilly"},{"DOI":"10.13039\/100002491","name":"BMS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The session on other forms of vasculitis included a masterful review on IgG4-related disease (IgG4-RD) following which two research studies evaluating therapeutic agents and one study on histopathologic findings of IgG4-RD were presented. Peyronel F., et al. discussed the results of a prospective multicentre randomized clinical trial evaluating methotrexate for patients with retroperitoneal fibrosis. Methotrexate, in combination with a tapering regimen of glucocorticoids, was effective in inducing remission and allows use of lower cumulative prednisone doses. Hobbelink J., et al. evaluated the histopathologic scoring system from the ACR\/EULAR Classification criteria for IgG4-RD. Their study found that these criteria were able to distinguish patients with confirmed and suspected IgG4-RD. Trivioli G et al. retrospectively evaluated rituximab in adult-onset IgA Vasculitis (IgAV) and crescentic IgA Nephropathy (cIgAN). Rituximab resulted in high rate of renal response in IgAV but remission rates in cIgAN remained lower with poorer renal outcomes compared with IgAV.<\/jats:p>","DOI":"10.1093\/rheumatology\/keae386","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T09:17:34Z","timestamp":1741771054000},"page":"i134-i136","source":"Crossref","is-referenced-by-count":1,"title":["Highlights from the breakout session: other forms of vasculitis"],"prefix":"10.1093","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7335-7321","authenticated-orcid":false,"given":"Tanaz A","family":"Kermani","sequence":"first","affiliation":[{"name":"Division of Rheumatology, University of California Los Angeles , Los Angeles, CA,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7708-2487","authenticated-orcid":false,"given":"Kenneth J","family":"Warrington","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Mayo Clinic , Rochester, MN,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,3,12]]},"reference":[{"key":"2025031209170477400_keae386-B1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 revised International Chapel Hill consensus conference nomenclature of vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2025031209170477400_keae386-B2","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/modpathol.2012.72","article-title":"Consensus statement on the pathology of IgG4-related disease","volume":"25","author":"Deshpande","year":"2012","journal-title":"Mod Pathol"},{"key":"2025031209170477400_keae386-B3","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/s41577-023-00871-z","article-title":"The unique properties of IgG4 and its roles in health and disease","volume":"23","author":"Rispens","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"2025031209170477400_keae386-B4","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/s41584-020-0500-7","article-title":"IgG4-related disease: an update on pathophysiology and implications for clinical care","volume":"16","author":"Perugino","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"2025031209170477400_keae386-B5","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1007\/s40744-023-00593-7","article-title":"Efficacy and safety of inebilizumab in IgG4-related disease: protocol for a randomized controlled trial","volume":"10","author":"Perugino","year":"2023","journal-title":"Rheumatol Ther"},{"key":"2025031209170477400_keae386-B6","doi-asserted-by":"crossref","first-page":"e442","DOI":"10.1016\/S2665-9913(23)00157-1","article-title":"Evaluation of the safety, efficacy, and mechanism of action of obexelimab for the treatment of patients with IgG4-related disease: an open-label, single-arm, single centre, phase 2 pilot trial","volume":"5","author":"Perugino","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"2025031209170477400_keae386-B7","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1136\/annrheumdis-2013-203267","article-title":"Methotrexate plus prednisone in patients with relapsing idiopathic retroperitoneal fibrosis","volume":"72","author":"Alberici","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2025031209170477400_keae386-B8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/art.41120","article-title":"The 2019 American College of Rheumatology\/European League Against Rheumatism classification criteria for IgG4-related disease","volume":"72","author":"Wallace","year":"2020","journal-title":"Arthritis Rheumatol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/Supplement_1\/i134\/62374890\/keae386.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/Supplement_1\/i134\/62374890\/keae386.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T09:17:41Z","timestamp":1741771061000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/Supplement_1\/i134\/8069392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,1]]},"references-count":8,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2025,3,12]]},"published-print":{"date-parts":[[2025,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keae386","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2025,3,1]]}}}